Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Ergun, E; Maár, N; Ansari-Shahrezaei, S; Wimpissinger, B; Krepler, K; Wedrich, A; Stur, M.
Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
Am J Ophthalmol. 2006; 142(1):10-16
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Ansari Shahrezaei Siamak
Wedrich Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To examine the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration (AMD). Retrospective, interventional case series. Sixty eyes of 56 patients with neovascular AMD were treated with PDT with verteporfin followed by an intravitreal injection of 4 mg triamcinolone acetonide. The main outcome measures were visual acuity (VA), retreatment frequency with PDT (and triamcinolone), and frequency of side effects. Mean follow-up was 15.9 months (range 12 to 30 months, median 15 months). Twenty-three (38.3%) of 60 eyes had a stable result at 12 months' follow-up (that is, loss/gain <three lines) and 34 (56.7%) of 60 had a loss of 3 lines or more. Three patients (5%) had an improvement of 3 lines or more. Lesion type, patient age, and lesion size had no influence on the outcome, but baseline VA had a statistically significant effect (P = .006). The median number of PDT-intravitreal triamcinolone acetonide treatments was one. One-third (20 of 60) of all eyes had an increase in intraocular pressure (IOP) that required therapy. There were no cases of endophthalmitis, but 13 patients (21.6%) developed severe cataract that required surgery. The combination of PDT and intravitreal triamcinolone acetonide requires careful consideration as a treatment option for neovascular AMD. In our case series, this treatment combination did not prevent a considerable decrease in VA. The main benefit of this combination treatment was a low number of verteporfin treatments. Baseline VA was the main predictor of the final outcome.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology
Drug Therapy, Combination -
Female -
Follow-Up Studies -
Glucocorticoids - adverse effects Glucocorticoids - therapeutic use
Humans -
Injections -
Macular Degeneration - complications Macular Degeneration - drug therapy
Male -
Photochemotherapy -
Photosensitizing Agents - adverse effects Photosensitizing Agents - therapeutic use
Porphyrins - adverse effects Porphyrins - therapeutic use
Retreatment -
Retrospective Studies -
Triamcinolone Acetonide - adverse effects Triamcinolone Acetonide - therapeutic use
Visual Acuity -
Vitreous Body -

© Meduni Graz Impressum